Aktis Oncology (AKTS) investor relations material

Strategic vision and platform development

• Expanding radiopharmaceuticals to underserved patient groups using a proprietary mini-protein radioconjugate platform, with high tumor penetration and rapid clearance from normal tissues.

• Utilizes advanced screening libraries and generative AI to identify optimal candidates, supporting a differentiated pipeline.

• Maintains a strong capital position with $538 million in cash, providing runway into 2029 for continued investment and growth.

• Built an industry-leading, redundant supply chain for isotope sourcing and manufacturing, including a new GMP suite opening later this year and a scalable network of GMP partners.

• Collaboration with Eli Lilly enhances discovery capabilities and pipeline development.

Clinical pipeline and program progress

• Lead asset AKY-1189 targets Nectin-4, is in phase I-B dose escalation, has Fast Track designation for metastatic urothelial cancer, and shows strong tumor uptake and favorable safety.

• AKY-2519 targets B7-H3, with promising early data in prostate, lung, and colorectal cancers, and IND clearance received with phase I-B trials initiated in 2Q 2026.

• Both programs are designed for multi-indication development, with plans to expand into additional tumor types and maximize commercial potential.

• Ongoing and planned trials include NECTINIUM-2 (Nectin-4, data expected Q1 2027) and BActinium-1/2 (B7-H3, prostate and non-prostate basket studies), with two additional clinical candidates anticipated by October 2027.

• AKY-1189 and AKY-2519 have potential to address up to 193K and 215K patients, respectively, across multiple tumor types.

Market opportunity and competitive landscape

• Lead programs address large patient populations, with forecasted peak sales for comparables (PLUVICTO, PADCEV) ranging from $5.4B to $7.0B.

• Pricing benchmarks for similar therapies are $300K–$500K per year.